CLINICAL TRIALS PROFILE FOR PNEUMOCOCCAL 20-VALENT CONJUGATE VACCINE
✉ Email this page to a colleague
All Clinical Trials for pneumococcal 20-valent conjugate vaccine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00133549 ↗ | 9-valent CRM 197 Pneumococcal | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2000-11-01 | The purpose of this study is to evaluate the safety and immune response of a conjugated pneumococcal vaccine compared to a licensed 23-valent polysaccharide pneumococcal vaccine in elderly adults. Study participants will include 180 adults, 65 years of age or greater. Participants will be randomly assigned to 1 of 3 possible groups. Subjects will maintain a study diary to record side effects and oral temperatures for 7 days following each vaccination. Blood samples will be collected before and 1 month following each dose of vaccine or placebo. Participants will be involved in study related procedures for up to 268 days. |
| NCT00366678 ↗ | Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-10-01 | The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France. |
| NCT01235949 ↗ | Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment | Completed | GlaxoSmithKline | Phase 4 | 2010-11-12 | The aim of the current study is to determine whether ibuprofen, given as immediate or delayed prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune response in children receiving primary vaccination with GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine, co-administered with DTPa-combined vaccines, at 3, 4 and 5 months of age. In addition, this study will further evaluate the impact of prophylactic administration of paracetamol following primary vaccination with immediate or delayed administration or when given in an immediate manner at the time of the booster dose. |
| NCT01392378 ↗ | Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® | Completed | Pfizer | Phase 4 | 2011-08-01 | The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination. Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination. |
| NCT02097849 ↗ | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. | Completed | Biogen | Phase 2 | 2015-02-28 | Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response] and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T cell-dependent neoantigen response]. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pneumococcal 20-valent conjugate vaccine
Condition Name
| Condition Name for pneumococcal 20-valent conjugate vaccine | |
| Intervention | Trials |
| Pneumococcal Infection | 3 |
| Stage I Chronic Lymphocytic Leukemia | 1 |
| Multiple Myeloma | 1 |
| Stage I Small Lymphocytic Lymphoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for pneumococcal 20-valent conjugate vaccine
Trials by Country
Clinical Trial Progress for pneumococcal 20-valent conjugate vaccine
Clinical Trial Phase
Clinical Trial Sponsors for pneumococcal 20-valent conjugate vaccine
Sponsor Name
